Sugi Predict

Sugi Predict / Compounds / SCHEMBL2152989

SCHEMBL2152989

SCHEMBL2152989

O=c1ccc(-c2ccc(O)cc2)n[nH]1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.67
▸ MEN1 O00255 1/20 0.67
▸ KMT2A Q03164 1/20 0.67
▸ CYP1A2 P05177 2/20 0.66
▸ PDE3B Q13370 5/20 0.56
▸ PDE3A Q14432 5/20 0.56
▸ MAPT P10636 1/20 0.53
▸ PDE4A P27815 3/20 0.51
▸ PDE4B Q07343 3/20 0.51
▸ PDE4C Q08493 3/20 0.51
▸ PDE4D Q08499 3/20 0.51
▸ CA12 O43570 1/20 0.51
▸ ALPL P05186 1/20 0.51
▸ ALK Q9UM73 1/20 0.45
▸ APP P05067 1/20 0.45
▸ HRH3 Q9Y5N1 4/20 0.44
▸ JAK2 O60674 1/20 0.44
▸ NTRK1 P04629 1/20 0.44
▸ RET P07949 1/20 0.44
▸ PDGFRB P09619 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3452908 0.89 LMNA (0.80) LMNAMEN1KMT2ACYP1A2PDE3B
SCHEMBL9687063 0.82 LMNA (0.69) LMNAMEN1KMT2ACYP1A2PDE3B
SCHEMBL481916 0.80 LMNA (0.67) LMNAMEN1KMT2ACYP1A2PDE3B
SCHEMBL11035831 0.80 LMNA (1.00) LMNAMEN1KMT2ACYP1A2PDE3B
SCHEMBL928226 0.80 LMNA (0.67) LMNAMEN1KMT2ACYP1A2PDE3B
SCHEMBL4122238 0.80 LMNA (0.67) LMNAMEN1KMT2ACYP1A2PDE3B
SCHEMBL1392640 0.80 LMNA (0.67) LMNAMEN1KMT2ACYP1A2PDE3B
SCHEMBL928205 0.80 LMNA (0.67) LMNAMEN1KMT2ACYP1A2PDE3B
SCHEMBL1640817 0.79 CYP1A2 (0.65) LMNAMEN1KMT2ACYP1A2PDE3B
SCHEMBL11140405 0.79 LMNA (0.56) LMNAMEN1KMT2ACYP1A2PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104761717-A Polyaryletherketone quadripolymer and preparation method thereof CHANGCHUN APPLIED CHEMISTRY 2015-07-08 — — CN claimed
CN-106243675-A A kind of antibacterial PAEK material and preparation method thereof 中国科学院长春应用化学研究所 2016-12-21 — — CN disclosed
CN-106243676-A A kind of self-lubricating PAEK material and preparation method thereof 中国科学院长春应用化学研究所 2016-12-21 — — CN disclosed
CN-104761717-A Polyaryletherketone quadripolymer and preparation method thereof CHANGCHUN APPLIED CHEMISTRY 2015-07-08 — — CN disclosed
CN-104725987-A Coating combination and metal material CHANGCHUN APPLIED CHEMISTRY 2015-06-24 — — CN disclosed
CN-104693134-A S-triazine derivate monomer and preparing method for polyarylether fluorescent material UNIV SHANDONG AGRICULTURE 2015-06-10 — — CN disclosed
CN-101678214-B Aryl ether pyridazinone derivatives MERCK PATENT GMBH 2013-06-19 — — CN disclosed
US-8445489-B2 Aryl ether pyridazinone derivatives MERCK PATENT GMBH (DE) 2013-05-21 — — US disclosed
US-8445489-B2 Aryl ether pyridazinone derivatives MERCK PATENT GMBH (DE) 2013-05-21 — — US disclosed
US-8445489-B2 Aryl ether pyridazinone derivatives MERCK PATENT GMBH (DE) 2013-05-21 — — US disclosed
US-20080293719-A1 Pyridiazinone Derivatives for the Treatment of Tumours MERCK PATENT GESELLSCHAFT (DE) 2008-11-27 — — US disclosed
EP-1960370-A1 PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT Merck Patent GmbH (DE) 2008-08-27 — — EP disclosed
WO-2007065518-A1 PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT MERCK PATENT GMBH (DE) 2007-06-14 — — WO disclosed
WO-2007065518-A1 PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT MERCK PATENT GMBH (DE) 2007-06-14 — — WO disclosed
CN-1124267-C Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides ROHM & HAAS (US) 2003-10-15 — — CN disclosed
CN-1143637-A Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides ROHM & HAAS (US) 1997-02-26 — — CN disclosed
EP-0330242-B1 PYRIDAZINONE DERIVATIVES, THEIR PREPARATION AND USE Sankyo Company Limited (JP) 1993-09-22 — — EP disclosed
US-5135932-A 2-HYDROXYPROPYLAMINO-ALKYL-BENZIMIDAZOLY-5-YL DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEART DISEASE DR. KARL THOMAE GMBH (DE) 1992-08-04 — — US disclosed
US-5053338-A Hydrolysis of ester to obtain an optically enriched mixture of a phenol enantiomer GLAXO INC. (US) 1991-10-01 — — US disclosed
US-4052395-A AGRICULTURAL FUNGICIDAL COMPOSITIONS CONTAINING 6-(SUBSTITUTED PHENYL)-PYRIDAZINONES AND SAID PYRIDAZINONES SANKYO COMPANY LIMITED (JA) 1977-10-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293719-A1 Pyridiazinone Derivatives for the Treatment of Tumours MET, RET, ERBB2 LMNA 2429/4885MEN1 167/4885KMT2A 839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.